SurgePays (SURG) Projected to Post Quarterly Earnings on Wednesday

Key Points

• SurgePays (NASDAQ:SURG) is set to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of $0.31 per share and revenues of $16.14 million.
• The company recently reported a Q1 loss of $0.38 per share, slightly surpassing analysts' expectations, along with revenues of $10.58 million, which also beat consensus estimates.
• Despite trading down 2.7% to $2.63, SurgePays has seen ratings upgrades from analysts, with Ascendiant Capital Markets raising their price target to $9.00 and changing their rating to "buy."

SurgePays (NASDAQ:SURG - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 13th. Analysts expect SurgePays to post earnings of ($0.31) per share and revenue of $16.14 million for the quarter.

SurgePays (NASDAQ:SURG - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The medical equipment provider reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. SurgePays had a negative net margin of 136.37% and a negative return on equity of 206.01%. The firm had revenue of $10.58 million during the quarter, compared to the consensus estimate of $9.80 million. During the same quarter in the previous year, the firm posted $0.07 EPS. On average, analysts expect SurgePays to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SurgePays Price Performance

Shares of SURG traded up $0.02 during midday trading on Friday, hitting $2.92. 186,507 shares of the company traded hands, compared to its average volume of 80,795. The firm has a 50 day moving average of $2.93 and a 200-day moving average of $2.36. SurgePays has a 52 week low of $1.05 and a 52 week high of $3.47. The stock has a market cap of $59.60 million, a price-to-earnings ratio of -1.05 and a beta of 0.44. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.41 and a current ratio of 1.72.

Hedge Funds Weigh In On SurgePays

Several hedge funds have recently added to or reduced their stakes in SURG. Goldman Sachs Group Inc. purchased a new stake in SurgePays in the first quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its position in shares of SurgePays by 34,091.3% during the first quarter. Jones Financial Companies Lllp now owns 51,287 shares of the medical equipment provider's stock worth $106,000 after purchasing an additional 51,137 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of SurgePays by 61.0% during the second quarter. Cetera Investment Advisers now owns 45,400 shares of the medical equipment provider's stock worth $141,000 after purchasing an additional 17,200 shares in the last quarter. 6.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on SURG shares. Wall Street Zen upgraded shares of SurgePays from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Ascendiant Capital Markets upped their price objective on shares of SurgePays from $8.75 to $9.00 and gave the company a "buy" rating in a research note on Monday, June 16th.

SurgePays Company Profile

SurgePays, Inc, together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities.